BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Chroma Therapeutics 



Abingdon      England
Phone: n/a Fax:


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology

Segment
Start Up





 Company News
Chroma Therapeutics Release: Tosedostat Opal Study in Acute Myeloid Leukemia Published in Lancet Oncology 3/4/2013 11:51:59 AM
Chroma Therapeutics Extends Collaboration With GlaxoSmithKline (GSK) and Advances Novel Targeted Agent Towards Clinical Development; Receives Milestone Payment 1/3/2013 10:24:05 AM
Cell Therapeutics, Inc. (CTIC) and Chroma Therapeutics Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 12/13/2011 7:58:02 AM
Chroma Therapeutics and Cell Therapeutics, Inc. (CTIC) Announce New Positive Interim Phase II Data for Tosedostat in AML OPAL Study, Revealed at American Society of Clinical Oncology 6/8/2011 9:33:05 AM
Chroma Therapeutics Release: New Tosedostat Data Selected for Oral Discussion Session at the 2011 American Society of Clinical Oncology Annual Meeting 5/25/2011 11:35:47 AM
Cell Therapeutics, Inc. (CTIC) Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers 3/14/2011 7:55:34 AM
Chroma Therapeutics to Present at 29th Annual J.P. Morgan Healthcare Conference 1/6/2011 10:39:08 AM
Chroma Therapeutics Advances Novel Targeted Agent into Development; Receives Milestone Payment from GlaxoSmithKline (GSK) 8/24/2010 11:32:42 AM
GlaxoSmithKline (GSK) Signs Potential $1 Billion Drug Deal with Chroma Therapeutics 6/23/2009 8:05:38 AM
Invitrogen Corporation (IVGN) and Chroma Therapeutics Extend Kinase Screening Partnership 2/25/2008 8:47:43 AM
12